Quantcast

Latest Dana-Farber Cancer Institute Stories

2012-12-14 15:12:38

Previously unknown protein function could be a treatment target Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs. The researchers report in the Dec. 14 issue of Science that the molecular...

2012-12-11 12:01:29

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting. The combination of two immunosuppressive compounds -- tacrolimus plus sirolimus -- did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from...

2012-12-11 12:00:01

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston. The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute...

2012-11-23 10:50:21

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. The treatment of gastrointestinal stromal tumor, or GIST, even in its advanced metastatic stage, has been dramatically improved with two oral targeted drugs — imatinib (Gleevec) and...

2012-11-14 11:19:52

Terminally ill cancer patients who have an early talk with their physician about care at the end-of-life are less likely to receive aggressive therapy — and more likely to enter hospice care — than patients who delay such discussions until the days and weeks before death, a new study by Dana-Farber Cancer Institute researchers suggests. Having a conversation about end-of-life care several months before their condition begins to deteriorate may enable patients to think through...

2012-10-26 00:40:03

Findings from a nationwide study led by researchers at Dana-Farber Cancer Institute suggest that patients with advanced lung or colorectal cancer are frequently mistaken in their beliefs that chemotherapy can cure their disease. The study, published in the Oct. 25 issue of the New England Journal of Medicine, found that 69 percent of patients with advanced lung cancer and 81 percent of patients with advanced colorectal cancer did not understand that the chemotherapy they were receiving was...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related